Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe..  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive Supplemental or secondary. In the context of Parkinson's, adjunctive medications are used to enhance the effects of levodopa. treatment to levodopaThe medication most commonly given to control the movement symptoms of Parkinson’s, usually with carbidopa. It is converted in the brain into dopamine. in Parkinson’s disease patients to reduce OFF time When medication is not working well. Symptoms become more noticeable and movement becomes more difficult..

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
National Parkinson Foundation Expands Expert Care Network in Italy
Wednesday, November 2, 2016

MIAMI — The National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, announced today a new partnership with the Fresco Institute Italia to improve the quality of Parkinson’s care in Italy. The NPF Center of Excellence global network embodies the world’s leading Parkinson’s specialists focused on changing the course of Parkinson’s disease (PD). 

U.S. Senator Cory Booker Serves as Grand Marshal of Moving Day® Miami
Tuesday, November 1, 2016

MIAMI — The National Parkinson Foundation is pleased to announce that U.S. Senator Cory Booker (NJ) will serve as the Grand Marshal of the 5th Annual Moving Day Miami, the foundation’s walk to raise awareness of Parkinson’s disease in South Florida. The event, presented by Terranova Corporation, begins at 9 a.m.

PDF Champion to Host 14th Annual Music for Parkinson’s Research Concert on Sunday, November 13 in Rye, NY
Monday, October 24, 2016

White Plains, NY, clinical psychologist David Eger, Ph.D., is on a mission to help end Parkinson’s through music.  The 14th annual Music for Parkinson’s Research concert, which benefits the Parkinson’s Disease Foundation’s (PDF) research programs, will take place on Sunday, November 13 at 3:30 PM at the Congregation Emanu-El in Rye, NY.  The chamber music concert is organized by Dr.

PDF Recognizes Scholars of Edmond J. Safra Visiting Nurse Faculty Program for Outstanding Efforts in Nursing Education
Wednesday, October 19, 2016

The Parkinson’s Disease Foundation (PDF) congratulates Laura Kelly, Ph.D., R.N., A.N.P.-C., and Cheryl Leiningen, D.N.P., R.N., A.N.P.-C., Scholars of The Edmond J. Safra Visiting Nurse Faculty Program at PDF and 2016 recipients of the program’s annual Alumni Award for outstanding work in nursing education. Drs.

Patient Access Network Foundation and the National Parkinson Foundation Announce New Alliance to Provide Support for People Living With Parkinson’s Disease
Thursday, October 20, 2016

Washington, DC — The Patient Access Network (PAN) Foundation and the National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, today announced they are launching a new alliance to offer a broad range of support for people living with Parkinson’s disease.

The Parkinson’s Foundation Joins Global Community at 4th World Parkinson Congress in Portland, OR
Tuesday, September 20, 2016

New York, NY & Miami, FL —  The Parkinson's Foundation, recently formed by the merger of the National Parkinson Foundation® (NPF®) and the Parkinson’s Disease Foundation® (PDF®), is pleased to join the global Parkinson’s community this week at the 4th World Parkinson Congress (WPC) in Portland, OR.  The Parkinson’s Foundation offers interactive programs to encourage the Congress’ 4,000 delegates and those partici

National Parkinson Foundation Hosts Caregiver Summit
Monday, September 12, 2016

MIAMI — The National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, will be hosting the first-ever Caregiver Summit, geared specifically toward caregivers of people living with Parkinson’s disease (PD).

Refuting Claims Regarding Presidential Nominee Hillary Clinton and Parkinson’s Disease
Friday, September 9, 2016

The National Parkinson Foundation has received several questions about whether Hillary Clinton has Parkinson's disease (PD).

The allegations that Hillary Clinton suffers from Parkinson's disease have been reviewed by NPF's National Medical Director, Michael S. Okun, MD, and by others from NPF's Centers of Excellence network and been unanimously dismissed by every Parkinson's expert who has weighed in.

Parkinson's Disease Foundation Invests in Next Generation of Physical Therapy Leaders
Thursday, August 4, 2016

PDF Launches Innovative Pilot Training Program for Physical Therapy Educators

The Parkinson's Disease Foundation® (PDF®) is pleased to announce the launch of the Physical Therapy Faculty Program to improve care for the nearly one million people in the United States living with Parkinson’s disease. The pilot program launched this week in Boston, MA.

National Parkinson Foundation (NPF) and the Parkinson’s Disease Foundation (PDF) Complete Merger to Form the Parkinson’s Foundation
Monday, August 1, 2016

New York and Miami, August 1, 2016—The Boards of Directors of the National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF) announced today that they have finalized the merger of the two non-profit organizations. The organization will operate as the Parkinson's Foundation with offices in New York City and Miami.

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.